Novartis Aktie
138,56
EUR
-1,20
EUR
-0,86
%
138,52
EUR
-1,48
EUR
-1,06
%
Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Novartis Aktie Analyse
| 25.04.19 | Novartis Hold | HSBC | |
| 25.04.19 | Novartis buy | Jefferies & Company Inc. | |
| 25.04.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 24.04.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 24.04.19 | Novartis Neutral | UBS AG | |
| 24.04.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 17.04.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 17.04.19 | Novartis buy | Jefferies & Company Inc. | |
|
Werbung
|
|||
| 16.04.19 | Novartis buy | Kepler Cheuvreux | |
| 12.04.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 10.04.19 | Novartis Underweight | Barclays Capital | |
| 10.04.19 | Novartis Underweight | Morgan Stanley | |
| 08.04.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 08.04.19 | Novartis Underweight | Barclays Capital | |
| 05.04.19 | Novartis Neutral | Credit Suisse Group | |
| 05.04.19 | Novartis Hold | Deutsche Bank AG | |
| 03.04.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 27.03.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 27.03.19 | Novartis buy | Jefferies & Company Inc. | |
| 25.03.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.03.19 | Novartis Neutral | UBS AG | |
| 26.02.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 06.02.19 | Novartis Hold | HSBC | |
| 04.02.19 | Novartis Hold | Deutsche Bank AG | |
| 01.02.19 | Novartis Underweight | Barclays Capital | |
| 01.02.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 31.01.19 | Novartis Neutral | Credit Suisse Group | |
| 31.01.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 31.01.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 30.01.19 | Novartis Hold | Deutsche Bank AG | |
| 30.01.19 | Novartis Neutral | UBS AG | |
| 30.01.19 | Novartis buy | Kepler Cheuvreux | |
| 30.01.19 | Novartis buy | Jefferies & Company Inc. | |
| 29.01.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 24.01.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 18.01.19 | Novartis Neutral | UBS AG | |
| 16.01.19 | Novartis Underweight | Barclays Capital | |
| 16.01.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 11.01.19 | Novartis Hold | Deutsche Bank AG | |
| 08.01.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 02.01.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 14.12.18 | Novartis Equal-Weight | Morgan Stanley | |
| 14.12.18 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 14.12.18 | Novartis buy | Merrill Lynch & Co., Inc. | |
| 13.12.18 | Novartis Conviction Buy | Goldman Sachs Group Inc. | |
| 11.12.18 | Novartis buy | Jefferies & Company Inc. | |
| 10.12.18 | Novartis Hold | Deutsche Bank AG | |
| 10.12.18 | Novartis buy | Kepler Cheuvreux | |
| 10.12.18 | Novartis Underweight | Barclays Capital | |
| 07.12.18 | Novartis Underweight | Barclays Capital | |
Werbung
Werbung